WO2017125031A1 - 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法 - Google Patents
血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法 Download PDFInfo
- Publication number
- WO2017125031A1 WO2017125031A1 PCT/CN2017/071625 CN2017071625W WO2017125031A1 WO 2017125031 A1 WO2017125031 A1 WO 2017125031A1 CN 2017071625 W CN2017071625 W CN 2017071625W WO 2017125031 A1 WO2017125031 A1 WO 2017125031A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- complex
- ahu377
- exp3174
- receptor antagonist
- angiotensin receptor
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
编号 | 2θ(°,±0.2) | 相对强度(%) |
1 | 4.35 | 70.97 |
2 | 5.15 | 100.00 |
3 | 5.90 | 32.67 |
4 | 9.00 | 2.80 |
5 | 10.15 | 3.40 |
6 | 12.80 | 5.21 |
7 | 15.02 | 5.59 |
8 | 15.85 | 8.27 |
9 | 16.81 | 2.57 |
10 | 20.27 | 2.39 |
11 | 22.09 | 2.48 |
12 | 23.79 | 1.34 |
13 | 26.22 | 1.87 |
编号 | 2θ(°,±0.2) | 相对强度(%) |
1 | 4.40 | 77.30 |
2 | 5.19 | 100.00 |
3 | 5.96 | 19.78 |
4 | 15.82 | 5.11 |
5 | 26.34 | 3.44 |
编号 | 2θ(°,±0.2) | 相对强度(%) |
1 | 4.40 | 77.30 |
2 | 5.19 | 100.00 |
3 | 5.96 | 19.78 |
4 | 15.82 | 5.11 |
5 | 26.34 | 3.44 |
Claims (18)
- 一系列由血管紧张素受体拮抗剂代谢产物与NEP抑制剂的复合物,其特征在于,所述复合物的结构单元如下:(aEXP3174·bAHU377)·xCa·nA其中a:b=1:0.25~4;x为0.5~3之间的数值;A指代水、甲醇、乙醇、2-丙醇、丙酮、乙酸乙酯、甲基-叔-丁基醚、乙腈、甲苯、二氯甲烷;n为0~3之间的数值。
- 根据权利要求1所述的由血管紧张素受体拮抗剂代谢产物与NEP抑制剂的复合物,其特征在于所述复合物的结构单元如下:(EXP3174·AHU377)·xCa·nH2O其中x为0.5~2之间的数值;n为0~3之间的数值。
- 根据权利要求2所述的由血管紧张素受体拮抗剂代谢产物与NEP抑制剂的复合物,其特征在于x为1.5~2之间的数值,n为1~3之间的数值。
- 根据权利要求2或3任意一项所述的由血管紧张素受体拮抗剂代谢产物与NEP抑制剂的复合物,其特征在于n为2~3之间的数值。
- 根据权利要求1-4任意一项所述的由血管紧张素受体拮抗剂代谢产物与NEP抑制剂的复合物,其特征在于所述复合物的结构单元如下:(EXP3174·AHU377)·1.5Ca·nH2O其中n为1~3之间的任意数值。
- 根据权利要求5所述的由血管紧张素受体拮抗剂代谢产物与NEP抑制剂的复合物,其特征在于n为2~3之间的任意数值。
- 根据权利要求1-4任意一项所述的由血管紧张素受体拮抗剂代谢产物与NEP抑制剂的复合物,其特征在于所述复合物的结构单元如下:(EXP3174·AHU377)·2Ca·nH2O其中n为1~3之间的任意数值。
- 根据权利要求7所述的由血管紧张素受体拮抗剂代谢产物与NEP抑制剂的复合物,其特征在于n为2~3之间的任意数值。
- 根据权利要求1-8任意一项所述的由血管紧张素受体拮抗剂代谢产物与NEP抑制剂的复合物,其特征在于所述复合物的结构单元为如下任一:(EXP3174·AHU377)·1.5Ca·1H2O;(EXP3174·AHU377)·1.5Ca·1.5H2O;(EXP3174·AHU377)·1.5Ca·2H2O;(EXP3174·AHU377)·1.5Ca·2.5H2O;(EXP3174·AHU377)·1.5Ca·3H2O;(EXP3174·AHU377)·2Ca·1H2O;(EXP3174·AHU377)·2Ca·1.5H2O;(EXP3174·AHU377)·2Ca·2H2O;(EXP3174·AHU377)·2Ca·2.5H2O;(EXP3174·AHU377)·2Ca·3H2O。
- 根据权利要求1-9任意一项所述的由血管紧张素受体拮抗剂代谢产物与NEP抑制剂的复合物,其特征在于所述复合物的XRD谱图在2θ为4.35°、5.15°、5.90°、12.80°、15.85°处具有衍射峰,可接受的误差范围±0.2°;或者所述复合物的XRD谱图在2θ为4.40°、5.19°、5.96°处具有衍射峰,可接受的误差范围±0.2°。
- 根据权利要求10所述的由血管紧张素受体拮抗剂代谢产物与NEP抑制剂的复合物,其特征在于所述复合物的XRD谱图还在2θ为9.00°、10.15°、15.02°处有衍射峰,可接受的误差范围±0.2°;或者所述复合物的XRD谱图还在2θ为15.82°、26.34°处具有衍射峰,可接受的误差范围±0.2°。
- 根据权利要求10-12任意一项所述的由血管紧张素受体拮抗剂代谢产物与NEP抑制剂的复合物,其特征在于所述复合物的XRD谱图如图1或图5所示。
- 根据权利要求1-13任意一项所述的由血管紧张素受体拮抗剂代谢产物与NEP抑制剂的复合物,其特征在于所述复合物的DSC谱图在94.4±10℃、164.1±10℃有两处失水吸热峰,在244.6±5℃处存在吸热峰;或者,所述复合物的DSC谱图在在95.4±10℃、166.4±10℃有两处失水吸热峰,在242.4±5℃存在吸热峰。
- 根据权利要求14所述的由血管紧张素受体拮抗剂代谢产物与NEP抑制剂的复合物,其特征在于所述复合物的DSC谱图如图2或图6所示
- 一种制备如权利要求1-15任意一项所述的由血管紧张素受体拮抗剂代谢产物与NEP抑制剂的复合物的方法,包括如下步骤:1)将AHU377盐游离后制备得到含有AHU377游离酸的溶液,脱溶;2)将步骤1)所得AHU377游离酸、EXP3174溶于适当的溶剂中;3)将药学上可接受的钙离子盐和/或钙离子氢氧化物溶于/悬浮于适当的溶剂;4)将步骤3)所得混合物缓慢加入到步骤2)所得溶液中,或者钙离子盐和/或钙离子氢氧化物直接以固体形态与溶剂分别先后投入反应体系中;5)搅拌析晶,过滤得到固体沉淀并干燥得到所述复合物;所述步骤1)中AHU377的盐为钙盐、镁盐、锌盐、铁盐、钠盐、胺盐、二乙胺盐、三乙胺之一,所述溶液为醋酸异丙酯;所述步骤2)中EXP3174与AHU377的摩尔比为0.7~1.2:1;所述步骤3)中所述钙离子盐中钙离子的量与AHU377的摩尔比为1.3~2:1;所述适当的溶剂为丙酮和/或异丙醇;另外,溶剂中还需加入适量的水,AHU377与水的质量/体积比为1~8:1g/ml;更优选的,当AHU377与水的质量/体积比为2.36:1g/ml时,反应得到复合物的结构单元为:(EXP3174·AHU377)·1.5Ca·2.5H2O;当AHU377与水的质量/体积比为3.93:1g/ml时,反应得到复合物的结构单元为:(EXP3174·AHU377)·1.5Ca·2H2O;所述步骤4)在室温至45℃之间的温度下进行。
- 一种如权利要求1-16任意一项所述的由血管紧张素受体拮抗剂代谢产物与NEP抑制剂的复合物用于制备治疗心力衰竭的药物的用途。
- 根据权利要求17所述的由血管紧张素受体拮抗剂代谢产物与NEP抑制剂的复合物用于制备治疗心力衰竭的药物的用途,其特征在于所述药物中含有占质量百分数为0.1~99.9%所述复合物。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210026536.5A CN114315801B (zh) | 2016-01-20 | 2017-01-19 | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法 |
US16/071,377 US11026925B2 (en) | 2016-01-20 | 2017-01-19 | Angiotensin II receptor antagonist metabolite and NEP inhibitor composite and preparation method thereof |
RU2018126603A RU2723642C1 (ru) | 2016-01-20 | 2017-01-19 | Соединения метаболита антагониста рецептора ангиотензина ii и ингибитора nep, и способы их получения |
KR1020187023857A KR102150383B1 (ko) | 2016-01-20 | 2017-01-19 | 안지오텐신 ii 수용체 길항제 대사물질과 nep 억제제의 화합물, 및 이의 제조 방법 |
CN201780004975.3A CN108473474B (zh) | 2016-01-20 | 2017-01-19 | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法 |
EP17741062.8A EP3406610A4 (en) | 2016-01-20 | 2017-01-19 | ANGIOTENSIN II RECEPTOR ANTAGONIST METABOLIT AND NEP INHIBITOR COMPOSITION AND METHOD OF PREPARING THEREOF |
MX2018008531A MX2018008531A (es) | 2016-01-20 | 2017-01-19 | Compuestos del metabolito del antagonista del receptor de angiotensina ii y del inhibidor de nep, y metodos de preparacion de los mismos. |
CA3016258A CA3016258A1 (en) | 2016-01-20 | 2017-01-19 | Compounds of angiotensin ii receptor antagonist metabolite and nep inhibitor, and preparation methods thereof |
AU2017209250A AU2017209250B2 (en) | 2016-01-20 | 2017-01-19 | Angiotensin II receptor antagonist metabolite and NEP inhibitor composite, and preparation method thereof |
ZA2018/05376A ZA201805376B (en) | 2016-01-20 | 2018-08-13 | Angiotensin ii receptor antagonist metabolite and nep inhibitor composite, and preparation method thereof |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610038846.3 | 2016-01-20 | ||
CN201610038846 | 2016-01-20 | ||
CN201610193099 | 2016-03-30 | ||
CN201610193099.0 | 2016-03-30 | ||
CN201610430248.0 | 2016-06-16 | ||
CN201610430248 | 2016-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017125031A1 true WO2017125031A1 (zh) | 2017-07-27 |
Family
ID=59361369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/071625 WO2017125031A1 (zh) | 2016-01-20 | 2017-01-19 | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US11026925B2 (zh) |
EP (1) | EP3406610A4 (zh) |
KR (1) | KR102150383B1 (zh) |
CN (2) | CN108473474B (zh) |
AU (1) | AU2017209250B2 (zh) |
CA (1) | CA3016258A1 (zh) |
MX (1) | MX2018008531A (zh) |
RU (1) | RU2723642C1 (zh) |
TW (1) | TWI657826B (zh) |
WO (1) | WO2017125031A1 (zh) |
ZA (1) | ZA201805376B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020238884A1 (zh) * | 2019-05-30 | 2020-12-03 | 深圳信立泰药业股份有限公司 | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途 |
WO2020238885A1 (zh) * | 2019-05-30 | 2020-12-03 | 深圳信立泰药业股份有限公司 | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的治疗方法 |
WO2021052441A1 (zh) | 2019-09-20 | 2021-03-25 | 深圳信立泰药业股份有限公司 | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途 |
WO2021093697A1 (zh) * | 2019-11-11 | 2021-05-20 | 深圳信立泰药业股份有限公司 | 血管紧张素ii受体拮抗剂与nep抑制剂的复合物及其制备方法 |
WO2021143898A1 (zh) * | 2020-01-19 | 2021-07-22 | 深圳信立泰药业股份有限公司 | Arb代谢产物与nep抑制剂的复合物新晶型及其制备方法 |
WO2021254409A1 (zh) * | 2020-06-18 | 2021-12-23 | 深圳信立泰药业股份有限公司 | 一种复合物的药物组合物及其制备方法 |
WO2022037512A1 (zh) * | 2020-08-17 | 2022-02-24 | 深圳信立泰药业股份有限公司 | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的心衰应用 |
WO2022111493A1 (zh) * | 2020-11-25 | 2022-06-02 | 深圳信立泰药业股份有限公司 | Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途 |
WO2023025220A1 (zh) * | 2021-08-26 | 2023-03-02 | 深圳信立泰药业股份有限公司 | 一种ARNi与钙离子拮抗剂的药物组合物与应用 |
WO2024027779A1 (zh) * | 2022-08-04 | 2024-02-08 | 深圳信立泰药业股份有限公司 | ARNi化合物新晶型及其制备方法与应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190219A1 (ar) | 2017-05-09 | 2019-09-22 | Cardix Therapeutics LLC | تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007056546A1 (en) * | 2005-11-09 | 2007-05-18 | Novartis Ag | Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor |
CN104826115A (zh) * | 2015-04-19 | 2015-08-12 | 浙江巨泰药业有限公司 | 一种抗心衰药物组合物及其制备方法 |
CN105503760A (zh) * | 2014-10-10 | 2016-04-20 | 上海翰森生物医药科技有限公司 | 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用 |
CN105669581A (zh) * | 2015-11-09 | 2016-06-15 | 成都苑东生物制药股份有限公司 | 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物 |
CN106138041A (zh) * | 2015-04-15 | 2016-11-23 | 苏州朗科生物技术有限公司 | 一种双重作用的氯沙坦复合物 |
CN106146472A (zh) * | 2015-04-15 | 2016-11-23 | 苏州朗科生物技术有限公司 | 一种双重作用的阿利沙坦复合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101024643A (zh) | 2006-02-20 | 2007-08-29 | 上海艾力斯医药科技有限公司 | 咪唑-5-羧酸类衍生物、制备方法及其应用 |
CN105963296B (zh) * | 2015-03-12 | 2020-01-21 | 深圳信立泰药业股份有限公司 | 一种含有阿利沙坦酯或其盐或其水解产物或其水解产物盐的药物组合物及其用途 |
-
2017
- 2017-01-19 CA CA3016258A patent/CA3016258A1/en active Pending
- 2017-01-19 CN CN201780004975.3A patent/CN108473474B/zh active Active
- 2017-01-19 AU AU2017209250A patent/AU2017209250B2/en active Active
- 2017-01-19 WO PCT/CN2017/071625 patent/WO2017125031A1/zh active Application Filing
- 2017-01-19 EP EP17741062.8A patent/EP3406610A4/en active Pending
- 2017-01-19 US US16/071,377 patent/US11026925B2/en active Active
- 2017-01-19 MX MX2018008531A patent/MX2018008531A/es unknown
- 2017-01-19 RU RU2018126603A patent/RU2723642C1/ru active
- 2017-01-19 KR KR1020187023857A patent/KR102150383B1/ko active IP Right Grant
- 2017-01-19 CN CN202210026536.5A patent/CN114315801B/zh active Active
- 2017-01-20 TW TW106102063A patent/TWI657826B/zh active
-
2018
- 2018-08-13 ZA ZA2018/05376A patent/ZA201805376B/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007056546A1 (en) * | 2005-11-09 | 2007-05-18 | Novartis Ag | Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor |
CN105503760A (zh) * | 2014-10-10 | 2016-04-20 | 上海翰森生物医药科技有限公司 | 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用 |
CN106138041A (zh) * | 2015-04-15 | 2016-11-23 | 苏州朗科生物技术有限公司 | 一种双重作用的氯沙坦复合物 |
CN106146472A (zh) * | 2015-04-15 | 2016-11-23 | 苏州朗科生物技术有限公司 | 一种双重作用的阿利沙坦复合物 |
CN104826115A (zh) * | 2015-04-19 | 2015-08-12 | 浙江巨泰药业有限公司 | 一种抗心衰药物组合物及其制备方法 |
CN105669581A (zh) * | 2015-11-09 | 2016-06-15 | 成都苑东生物制药股份有限公司 | 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3406610A4 * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020238884A1 (zh) * | 2019-05-30 | 2020-12-03 | 深圳信立泰药业股份有限公司 | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途 |
WO2020238885A1 (zh) * | 2019-05-30 | 2020-12-03 | 深圳信立泰药业股份有限公司 | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的治疗方法 |
CN113286789A (zh) * | 2019-05-30 | 2021-08-20 | 深圳信立泰药业股份有限公司 | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途 |
CN114452287B (zh) * | 2019-05-30 | 2023-05-12 | 深圳信立泰药业股份有限公司 | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途 |
TWI784276B (zh) * | 2019-05-30 | 2022-11-21 | 大陸商深圳信立泰藥業股份有限公司 | 血管緊張素ii受體拮抗劑代謝產物與nep抑制劑的複合物的新用途 |
CN113286789B (zh) * | 2019-05-30 | 2022-03-11 | 深圳信立泰药业股份有限公司 | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途 |
CN114452287A (zh) * | 2019-05-30 | 2022-05-10 | 深圳信立泰药业股份有限公司 | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途 |
WO2021052441A1 (zh) | 2019-09-20 | 2021-03-25 | 深圳信立泰药业股份有限公司 | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途 |
EP4032532A4 (en) * | 2019-09-20 | 2023-10-04 | Shenzhen Salubris Pharmaceuticals Co. Ltd | USES OF A COMPLEX CONSISTING OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST METABOLISM AND A NEP INHIBITOR IN THE TREATMENT OF HEART FAILURE |
JP7316449B2 (ja) | 2019-09-20 | 2023-07-27 | シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド | 心不全治療におけるアンジオテンシンii受容体アンタゴニスト代謝産物とnep阻害剤との複合体の使用 |
TWI809313B (zh) * | 2019-09-20 | 2023-07-21 | 大陸商深圳信立泰藥業股份有限公司 | 血管緊張素ii受體拮抗劑代謝產物與nep抑制劑的複合物的新心衰用途 |
JP2022545904A (ja) * | 2019-09-20 | 2022-11-01 | シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド | 心不全治療におけるアンジオテンシンii受容体アンタゴニスト代謝産物とnep阻害剤との複合体の使用 |
CN114728944A (zh) * | 2019-11-11 | 2022-07-08 | 深圳信立泰药业股份有限公司 | 血管紧张素ii受体拮抗剂与nep抑制剂的复合物及其制备方法 |
CN114728944B (zh) * | 2019-11-11 | 2023-09-15 | 深圳信立泰药业股份有限公司 | 血管紧张素ii受体拮抗剂与nep抑制剂的复合物及其制备方法 |
WO2021093697A1 (zh) * | 2019-11-11 | 2021-05-20 | 深圳信立泰药业股份有限公司 | 血管紧张素ii受体拮抗剂与nep抑制剂的复合物及其制备方法 |
CN114945564A (zh) * | 2020-01-19 | 2022-08-26 | 深圳信立泰药业股份有限公司 | Arb代谢产物与nep抑制剂的复合物新晶型及其制备方法 |
CN114945564B (zh) * | 2020-01-19 | 2023-06-30 | 深圳信立泰药业股份有限公司 | Arb代谢产物与nep抑制剂的复合物新晶型及其制备方法 |
WO2021143898A1 (zh) * | 2020-01-19 | 2021-07-22 | 深圳信立泰药业股份有限公司 | Arb代谢产物与nep抑制剂的复合物新晶型及其制备方法 |
CN114096530B (zh) * | 2020-06-18 | 2022-11-15 | 深圳信立泰药业股份有限公司 | 一种复合物的药物组合物及其制备方法 |
CN114096530A (zh) * | 2020-06-18 | 2022-02-25 | 深圳信立泰药业股份有限公司 | 一种复合物的药物组合物及其制备方法 |
WO2021254409A1 (zh) * | 2020-06-18 | 2021-12-23 | 深圳信立泰药业股份有限公司 | 一种复合物的药物组合物及其制备方法 |
WO2022037512A1 (zh) * | 2020-08-17 | 2022-02-24 | 深圳信立泰药业股份有限公司 | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的心衰应用 |
WO2022111493A1 (zh) * | 2020-11-25 | 2022-06-02 | 深圳信立泰药业股份有限公司 | Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途 |
WO2023025220A1 (zh) * | 2021-08-26 | 2023-03-02 | 深圳信立泰药业股份有限公司 | 一种ARNi与钙离子拮抗剂的药物组合物与应用 |
WO2024027779A1 (zh) * | 2022-08-04 | 2024-02-08 | 深圳信立泰药业股份有限公司 | ARNi化合物新晶型及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
US20200061025A1 (en) | 2020-02-27 |
TW201726177A (zh) | 2017-08-01 |
RU2723642C1 (ru) | 2020-06-17 |
AU2017209250A1 (en) | 2018-09-06 |
KR102150383B1 (ko) | 2020-09-02 |
US11026925B2 (en) | 2021-06-08 |
KR20180128393A (ko) | 2018-12-03 |
EP3406610A4 (en) | 2019-09-04 |
MX2018008531A (es) | 2019-05-15 |
ZA201805376B (en) | 2019-06-26 |
CN114315801B (zh) | 2023-06-20 |
CN114315801A (zh) | 2022-04-12 |
CN108473474A (zh) | 2018-08-31 |
CN108473474B (zh) | 2022-02-11 |
TWI657826B (zh) | 2019-05-01 |
CA3016258A1 (en) | 2017-07-27 |
EP3406610A1 (en) | 2018-11-28 |
AU2017209250B2 (en) | 2021-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017125031A1 (zh) | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法 | |
JP2020203936A (ja) | バルサルタンおよびahu−377を含む三ナトリウム塩超分子複合体の新規な結晶形及びその製造方法 | |
EP3054937B1 (en) | Spray dry formulations | |
ES2575100T3 (es) | Compuestos aromáticos sustituidos y usos farmacéuticos de los mismos | |
JP5844251B2 (ja) | 3−ペンチルフェニル酢酸の塩およびその薬学的使用 | |
RU2735547C2 (ru) | Фармацевтическая композиция, содержащая 2-{ 4-[n-(5,6-дифенилпиразин-2-ил)-n-изопропиламино]бутилокси} -n-(метилсульфонил)ацетамид | |
WO2016051393A2 (en) | Crystalline form iv of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof | |
TWI784276B (zh) | 血管緊張素ii受體拮抗劑代謝產物與nep抑制劑的複合物的新用途 | |
JP2023550428A (ja) | インテグリン阻害剤およびその使用 | |
CN112638903B (zh) | 舒欣啶盐 | |
CN114728944B (zh) | 血管紧张素ii受体拮抗剂与nep抑制剂的复合物及其制备方法 | |
WO2019033969A1 (zh) | 替米沙坦与氢氯噻嗪的共晶 | |
US20120214753A1 (en) | Pharmaceutical composition for oral administration | |
CN107980038A (zh) | 沙库巴曲钙盐 | |
WO2020238885A1 (zh) | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的治疗方法 | |
WO2021143898A1 (zh) | Arb代谢产物与nep抑制剂的复合物新晶型及其制备方法 | |
JP2019089822A (ja) | トピロキソスタットの新規結晶形及びその製造方法 | |
CN105348261A (zh) | 达比加群酯丙酮酸盐及其制备方法和应用 | |
CN103664880A (zh) | 一种新型抗凝血药物及其制备方法与应用 | |
CN105294652A (zh) | 雷贝拉唑钠化合物 | |
WO2016169030A1 (zh) | 吡啶胺化合物的富马酸盐及其晶体 | |
WO2023285706A1 (en) | Solid-state forms of 2-(3-(4-(1h-indazol-5-ylamino)quinazolin-2-yl )phenoxy)-n- isopropylacetamide methane sulfonic acid salt | |
CN103509004A (zh) | 达比加群酯咖啡酸盐及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17741062 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2018/008531 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20187023857 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018126603 Country of ref document: RU Ref document number: 1020187023857 Country of ref document: KR Ref document number: 2017741062 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 3016258 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2017741062 Country of ref document: EP Effective date: 20180820 |
|
ENP | Entry into the national phase |
Ref document number: 2017209250 Country of ref document: AU Date of ref document: 20170119 Kind code of ref document: A |